英文_印度品牌价值基金会（IBEF）_2024年印度生物技术行业报告_34页_1mb

报告摘要

Summary of the Document: Biotechnology in India

Core Content

The document provides an in-depth overview of the biotechnology industry in India, highlighting its global position, growth trajectory, start-up ecosystem, and investment opportunities. It also outlines recent trends, strategies, and government initiatives aimed at fostering innovation and development in the sector.

Main Points

Global Position

India is among the top 12 biotechnology destinations globally and the third-largest in the Asia-Pacific region.
It holds about 3–5% of the global biotechnology industry share.
India is the world's third-largest producer of recombinant Hepatitis B vaccine and the second-largest producer of BT cotton.
It is a leading supplier of DPT, BCG & measles vaccines, contributing 70% to WHO's vaccine supply.
The bio-economy in India has grown from US$ 8 billion in 2014 to US$ 130 billion in 2024, and is projected to reach US$ 300 billion by 2030.
India has 665 FDA-approved plants outside the US and 44% of the global ANDA (abbreviated new drug applications) market share.

Market Overview

The biotechnology sector is highly inventive and is growing rapidly.
It is expected to reach US$ 150 billion by 2025 and US$ 270–300 billion by 2030.
The bio-pharmaceuticals and medical devices segments account for nearly 79% of the total contribution.
India is a prime destination for contract manufacturing and clinical trials.
It exports vaccines to over 150 countries.
The Indian biotechnology industry is the largest in Asia-Pacific and has a significant global footprint.

Start-up Ecosystem

India has a strong start-up ecosystem, driven by improved ease of doing business, proof-of-concept funds, and favorable government policies.
The biotechnology industry has 6,500+ start-ups and is expected to reach 10,000 by 2025.
75 bio-incubators across 21 states/UTs support 1,800+ incubates.
BIRAC, a public sector undertaking of DBT, supports 60 bio-incubators and has launched various schemes such as SBIRI, BIPP, BioNEST, SITARE, PACE, SIIP, SEED, LEAP and Fund of Funds-AcE.
In FY21, 1,128 new biotech startups were registered, bringing the total to ~6,000 by 2023.

Key Industry Contacts

Biocon: Indian pharmaceutical company based in Bangalore, manufacturing generic active pharmaceutical ingredients.
Serum Institute of India: Manufacturer of vaccines including DPT, BCG, and Hepatitis B.
Panacea Biotec Limited: Innovation-driven biotech company involved in R&D, manufacturing, and marketing of pharmaceuticals, vaccines, and biosimilars.
Dr. Reddy's Laboratory Limited: Integrated pharmaceutical company providing affordable and innovative medicines.
Wockhardt: Global pharmaceutical and biotech organisation.
Jubilant Life Sciences Co: Engaged in pharmaceuticals, life science ingredients, and drug discovery.
AstraZeneca India Ltd.: Biopharmaceutical company based in Bengaluru, manufacturing medicines for cardiovascular, renal, metabolic, oncology, and respiratory diseases.
Bharat Biotech: Engaged in drug discovery, development, and manufacturing of vaccines, bio-therapeutics, and health care products.
Bharat Serums and Vaccines Ltd: Manufacturer of plasma derivatives, monoclonals, and diagnostic products.
Indian Immunologicals Limited: Manufacturer of animal and human vaccines including rabies, Hepatitis B, and Influenza vaccines.

Recent Trends and Strategies

Partnerships and Collaborations

Bharat Biotech developed the world's first intranasal vaccine for Covid-19, iNCOVACC, launched in December 2022.
Serum Institute of India partnered with Novavax to manufacture the Covid vaccine NVX-CoV2373 for the US market.
C-CAMP (Bengaluru) announced a next-generation Indo-Dutch collaboration to tackle Antimicrobial Resistance (AMR).
DBT launched a "One Health" consortium to survey zoonotic and transboundary pathogens.
Mylab Solutions partnered with Shilpa Biologicals to market and distribute AG Boost in India.
India and Finland agreed to expand cooperation in biotechnology and digital education.
India and Israel aim to strengthen innovation and start-up ties.
DBT and UNESCO-TWAS launched a fellowship program for foreign scholars from developing countries.

Growth Drivers

Strong demand for biotechnology products and services, driven by maternal and child health, antimicrobial resistance, vaccines, food and nutrition, and clean technologies.
Policy support includes the National Biopharma Mission, which supports 101 projects, 150+ organizations, and 30 MSMEs, creating 1,065+ employment opportunities.
Favorable FDI policies allow 100% FDI under the automatic route for greenfield pharmaceuticals and medical devices.
Infrastructure development includes 9 DBT-supported biotech parks and 60 BIRAC-supported bio-incubators.
Skill development initiatives such as LSSSDC and NSDC are supporting R&D and product innovation.

Opportunities

Investment Opportunities

India is a preferred destination for clinical trials due to its large patient pool, cost competitiveness, and well-educated physicians.
The clinical trials market is expected to grow significantly.
The medical devices market is projected to reach US$ 50 billion by 2025.
Bio-IT has immense growth potential due to the rising need for data transformation and the expansion of the IT sector.
Bio-agri is gaining importance due to the Union Budget 2021-22 focus on farm productivity and food security.
Biofuels and bioenergy are emerging as alternative resources to reduce import dependence on fossil fuels.

Upcoming Projects

Genome India Project in Bangalore, valued at US$ 2.15 million.
Mangalapuram Bio 360 Life Sciences Park Project - Phase II in Kerala.
Biotech Park in Pilibhit planned by the Uttar Pradesh government.

Conclusion

India's biotechnology sector is growing rapidly, supported by a strong start-up ecosystem, favorable policies, robust infrastructure, and global collaborations. With domestic and international demand, technological advancements, and government initiatives, the industry is poised for significant expansion in the coming years, expected to reach US$ 300 billion by 2030. The sector offers diverse opportunities in clinical trials, medical devices, bio-pharmaceuticals, bio-agri, and bio-IT, making it a key player in the global biotechnology market.